RANK-Ligand inhibitor associated osteonecrosis of the jaw

2013/01/01 by Rashad, Ashkan, Ralf Smeets, Max Heiland +2
Medicine · #610 Medical sciences #Bone and Joint Diseases #Bone health and treatments #Cancer Diagnosis and Treatment #Medicine #RANK-Ligand inhibitor #bisphosphonates #denosumab #jaw #osteonecrosis

paper · doi:10.3205/iprs000037

openalex publication_date 2013/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/22

Abstract

Osteonecrosis of the jaw may be caused by many different triggers. One of them is described to be the drug or medication related osteonecrosis of the jaw. Since many years bisphosphonates induced the dreaded diagnosis. Recently a drug named denosumab is reported to show similar effects on the jaw. In this case report we present a RANK-Ligand inhibitor associated osteonecrosis of the lower jaw and discuss the lights and shadows of this newly introduced drug.

Related

• Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
• Tocilizumab: Another medication related to osteonecrosis of the jaws? A case report and literature review
• CRITICAL REVIEW OF THE USE OF TERIPARATIDE IN THE TREATMENT OF THE MEDICATION RELATED OSTEONECROSIS OF THE JAWS
• Association between periodontal disease, tooth extraction, and medication‐related osteonecrosis of the jaw in women receiving bisphosphonates: A national cohort‐based study
• Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?